Search
Sign In
Sign In
Sources
8 Total Sources
FDA Halts Regenxbio's RGX-121 Study After 5 Spine MRI Findings, Sending Shares Down 22%
Left
20%
Center
60%
Right
20%
All
8
Left
1
Center
3
Right
1
Others
3
Yahoo Finance
18d ago
FDA Halts Regenxbio's RGX-121 Gene Therapy Study Over Spine MRI Findings
Yahoo Finance
18d ago
FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome
STAT
18d ago
FDA Pauses Regenxbio Gene Therapy Trial Over Spinal Masses
ua.news
18d ago
FDA again halts Regenxbio gene therapy trial over safety concerns | UA.NEWS
BioSpace
18d ago
REGENXBIO's Hunter syndrome gene therapy hit by FDA hold, stymieing resubmission plans - BioSpace
Barron's
18d ago
Regenxbio Stock Sinks 25% Following Surprise Finding in Gene Therapy Trial - Barron's
StockTitan
18d ago
REGENXBIO: FDA Holds RGX-121 After 5 MRI Findings | RGNX Stock News
PR Newswire
18d ago
REGENXBIO Announces Regulatory Update on RGX-121 for MPS II